Challenges in Diabetes Drug Manufacturing and Supply

The chapter addresses the complications faced by major insulin manufacturers like Eli Lilly and Novo Nordisk, including insulin scarcity and the shift towards GLP-1 drugs. It debates the ethical and financial dilemmas these companies encounter as they balance the development of newer medications with the needs of patients dependent on insulin. The discussion also highlights the intricacies and potential health risks associated with insulin shortages and the difficulties patients face when switching between different insulin products.